Lung cancer is responsible for approximately one-third of all cancer-related deaths in the U.S. each year. Chemotherapy has been largely ineffective in producing complete responses or cures in the advanced disease setting. Therefore, investigation of new paradigms, including novel therapeutic approaches and early detection, has become an urgent priority for the oncology community. Key to early detection is the development of biomarkers that are found in primary tumor and can be detected in biological fluids prior to advanced disease. These biomarkers may also be useful for predicting therapeutic response during clinical trials. In support of these critical needs, our laboratory has identified two excellent biomarkers, the p16 tumor suppressor gene and the O6-methylguanine-DNA methyltransferase (MGMT) repair gene, whose inactivations through aberrant CpG island promoter hypermethylation occur frequently and early in the development of NSCLC. Furthermore, inactivation of these genes has been detected in exfoliated cells from sputum and shown to precede clinical diagnosis of squamous cell carcinoma (SCC). Aberrant methylation of p16, MGMT, and death-associated protein (DAP) kinase has also been detected in serum from NSCLC patients irrespective of tumor stage. Utilizing specimens and patients on ECOG study E3598, """"""""A Phase III trial of Carboplatin, Paclitaxel and Radiotherapy, With or Without Thalidomide, in Patients With Stage III NSCLC,"""""""" these advances in cancer biology will be translated into the clinic to address several important questions. First, can the detection of gene dysfunction in critical genes through analysis of sputum and/or serum be used for screening or as prognostic factors? This question will be addressed by determining the predictive power of sputum and serum to detect NSCLC through analysis for aberrant methylation of the p16, MGMT, DAP-kinase, and TIMP-3 genes within these biological fluids. Second, does inactivation of genes such as p16, DAP-kinase, or TIMP-3 in NSCLCs affect survival? A recent study demonstrated that median survival was shorter for patients with adenocarcinoma in which the p16 gene was inactivated. Thus, this question will be addressed by determining whether inactivation of p16, DAP-kinase, or TIMP-3 genes can be used to predict survival for patients on E3598. Finally, can detection of methylation markers in serum be useful for cancer diagnosis and/or have predictive value for survival? This will be addressed with patients on E3598. Results could have a profound impact on defining the utility of sputum and serum for detecting NSCLC, predicting survival from these therapeutic regimens, and delineating whether the presence of these tumor markers in serum affect survival. The validation of these genes as biomarkers of lung cancer risk and their detection in sputum and/or serum could ultimately support chemoprevention trials for preventing lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA089551-02
Application #
6514867
Study Section
Special Emphasis Panel (ZRG1-CONC (01))
Program Officer
Wu, Roy S
Project Start
2001-06-01
Project End
2006-05-31
Budget Start
2002-06-01
Budget End
2003-05-31
Support Year
2
Fiscal Year
2002
Total Cost
$600,190
Indirect Cost
Name
Lovelace Biomedical & Environmental Research
Department
Type
DUNS #
045911138
City
Albuquerque
State
NM
Country
United States
Zip Code
87108
Belinsky, Steven A (2015) Unmasking the lung cancer epigenome. Annu Rev Physiol 77:453-74
Tessema, Mathewos; Yingling, Christin M; Liu, Yushi et al. (2014) Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. Carcinogenesis 35:1248-57
Tessema, Mathewos; Yingling, Christin M; Snider, Amanda M et al. (2014) GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer. J Thorac Oncol 9:784-93
Tessema, M; Yingling, C M; Thomas, C L et al. (2012) SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene 31:4107-16
Belinsky, Steven A; Schiller, Joan H; Stidley, Christine A (2008) DNA methylation biomarkers to assess therapy and chemoprevention for non-small cell lung cancer. Nutr Rev 66 Suppl 1:S24-6
Belinsky, S A; Grimes, M J; Casas, E et al. (2007) Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 96:1278-83
Machida, Emi Ota; Brock, Malcolm V; Hooker, Craig M et al. (2006) Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 66:6210-8